SCHEMBL3020850

SCHEMBL3020850

O=C(CNC(=O)[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@@H](O)[C@H]1O)NCP(=O)(O)O

nearest known ligand 0.78

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ENTPD2 Q9Y5L3 3/20 0.78
P2RY2 P41231 10/20 0.54
ENTPD1 P49961 1/20 0.53
P2RY6 Q15077 7/20 0.50
P2RY14 Q15391 4/20 0.50
SLC28A1 O00337 1/20 0.49
SLC28A2 O43868 1/20 0.49
SLC29A1 Q99808 1/20 0.49
SLC28A3 Q9HAS3 1/20 0.49
P2RY4 P51582 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020853 1.00 ENTPD2 (0.78) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL3013455 0.90 ENTPD2 (0.70) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL3013450 0.90 ENTPD2 (0.70) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL3023058 0.89 ENTPD2 (0.79) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL3023054 0.89 ENTPD2 (0.79) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL13210978 0.88 ENTPD2 (1.00) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL3020858 0.85 ENTPD2 (0.70) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL13211022 0.84 ENTPD2 (0.79) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL15859417 0.84 ENTPD2 (0.79) ENTPD2P2RY2ENTPD1P2RY6P2RY14
SCHEMBL15859418 0.84 ENTPD2 (0.79) ENTPD2P2RY2ENTPD1P2RY6P2RY14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100204182-A1 ECTONUCLEOTIDASE INHIBITORS RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN (DE) 2010-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204182-A1 ECTONUCLEOTIDASE INHIBITORS NT5E, NT5C2, ENTPD1 ENTPD2 10/4885P2RY2 21/4885ENTPD1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.